TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
3D Medicines, Inc. ( (HK:1244) ) has issued an announcement.
3D Medicines Inc. reported significant progress in the first half of 2025, leveraging a recovering biotech-focused capital market in Hong Kong. The company achieved stable revenue and met key R&D milestones, with notable advancements in the commercialization of Envafolimab, its first commercialized product, which saw a 1.3% increase in sales revenue in China. The company presented multiple research achievements at the 2025 ASCO Annual Meeting, highlighting the efficacy and safety of Envafolimab in various cancer treatments. These developments underscore 3D Medicines’ commitment to innovation-driven growth and global expansion, marking a new chapter in its operational strategy.
The most recent analyst rating on (HK:1244) stock is a Hold with a HK$8.50 price target. To see the full list of analyst forecasts on 3D Medicines, Inc. stock, see the HK:1244 Stock Forecast page.
More about 3D Medicines, Inc.
3D Medicines Inc. is an innovation-driven biopharmaceutical company focused on the commercialization of biotechnological advancements. The company is engaged in the development and promotion of nuclear drugs and mRNA platforms with global independent intellectual property rights, aiming to expand its market presence globally.
Average Trading Volume: 604,514
Technical Sentiment Signal: Buy
Current Market Cap: HK$1.92B
See more insights into 1244 stock on TipRanks’ Stock Analysis page.